Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Thomas Weisel Ups Harvard Bioscience to 'Outperform'


Thomas Weisel upgraded Harvard Bioscience (HBIO) to outperform from peer perform.

Analyst Paul Knight says the upgrade is based on: Strong second-quarter operating performance, vs. previous periods; a string of successful acquisition consolidations (Genomic Solutions, Gene Machines, and BioRobotics) that are expanding margins; and, potential growth benefit from improved pharmaceutical demand.

Knight notes second-quarter results marked the best performance in more than a year. He thinks Harvard Bioscience's position in the pharmceutical industry (65% exposure) leverages its business model to benefit from a spending up cycle that's driven by the conclusion of the Pfizer/Pharmacia consolidation. Knight sees 25 cents 2003 earnings per share, 30 cents per share for 2004, and 40 cents per share for 2005.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus